



## Cerebrolysin<sup>®</sup> reduces hospital stay in TBI patients

Lynne L.N. Lucena and Marla V. A. Briones. Effect of Cerebrolysin<sup>®</sup> in severe traumatic brain injury: A multi-center, retrospective cohort study. Clinical Neurology and Neurosurgery 216 (2022).


### The effective treatment after TBI

- Faster recovery
- Severe TBI Patients benefit from Cerebrolysin<sup>®</sup>
- Earlier discharge from hospital

**Cerebrolysin<sup>®</sup>**

Reconnecting Neurons.  
Empowering for Life.


## FASTER RECOVERY WITH CEREBROLYSIN®



### Consistent improvement with Cerebrolysin®

- Significant **GCS improvement** on **Day 21** and **Day 28**
- **Enhancement** of **patient mobility** with Cerebrolysin®


## SEVERE TBI PATIENTS BENEFITS FROM CEREBROLYSIN®



### Faster treatment response

- Higher chance of **achieving a GOS ≥ 4 at Day 14** in the Cerebrolysin® group
- A significantly higher percentage of Cerebrolysin® patients had a **favourable outcome** with a GOS score of **≥ 4, on Day 21 and Day 28**

# EARLIER DISCHARGE FROM HOSPITAL



## Shorter Length of Hospital Stay reduces economic costs

- Length of Hospital Stay (LOS) reduced **about 7 days** in the **Cerebrolysin®** group
- **High economic costs**, associated with long-term care, could be **reduced by shorter LOS**



- **Early improvment** in functional and neurological outcomes favours Cerebrolysin® treatment.
- 50% of severe TBI patients treated with Cerebrolysin® **improving to mild or moderate TBI** already at Day 14.
- The observation of a **shorter length of hospital stay** in the Cerebrolysin® group clearly supports the idea of faster recovery rates, measured by GCS and GOS.

# Cerebrolysin® dosage for Traumatic Brain Injury patients

Daily dosage	Initiation of treatment	Treatment Duration
20 – 50 ml	as soon as possible	7 – 30 days



**Title:** Effect of Cerebrolysin® in severe traumatic brain injury: A multi-center, retrospective cohort study

**Patients:** 42 Cerebrolysin® group + 45 Control group = 87 nonoperative severe TBI patients (GCS 5–7) in total

**Treatment:** For all patients: standard decompression protocol (osmotherapy with mannitol and hypertonic saline)

**Cerebrolysin® group:**

30ml/day Cerebrolysin® day 1-14

10ml/day Cerebrolysin® day 15-28

**Author:** Lynne L.N. Lucena and Marla V. A. Briones

**Journal:** Clinical Neurology and Neurosurgery 216 (2022)

**URL:** <https://www.sciencedirect.com/science/article/abs/pii/S030384672200097X>

Copyright © 2023 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria

ABBREVIATED PRESCRIBING INFORMATION – Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Cranio-cerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorization Holder: EVER Neuro Pharma GmbH, A-4866 Unterach Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC-CCDS Version 2.0/03.06.2016)

EVER Neuro Pharma GmbH  
Oberburgau 3  
4866 Unterach  
Austria  
[www.everpharma.com](http://www.everpharma.com)  
[www.cerebrolysin.com](http://www.cerebrolysin.com)